Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials

Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the reduction of ischaemic events in patients with acute coronary syndrome (ACS). However, this comes at the expense of increased bleeding. A guided selection of P2Y12 inhibiting therapy has the potential to overcome this l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal Jg. 43; H. 10; S. 959
Hauptverfasser:	Galli, Mattia, Benenati, Stefano, Franchi, Francesco, Rollini, Fabiana, Capodanno, Davide, Biondi-Zoccai, Giuseppe, Vescovo, Giovanni Maria, Cavallari, Larisa H, Bikdeli, Behnood, Ten Berg, Jurrien, Mehran, Roxana, Gibson, Charles Michael, Crea, Filippo, Pereira, Naveen L, Sibbing, Dirk, Angiolillo, Dominick J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 07.03.2022
Schlagworte:	Acute Coronary Syndrome Humans Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Prasugrel Hydrochloride - adverse effects Prasugrel Hydrochloride - therapeutic use Purinergic P2Y Receptor Antagonists - adverse effects Purinergic P2Y Receptor Antagonists - therapeutic use Randomized Controlled Trials as Topic Ticagrelor - adverse effects Ticagrelor - therapeutic use Treatment Outcome Antiplatelet therapy Prasugrel P2Y12 inhibitors Platelet function Clopidogrel Genetic testing Acute coronary syndrome Ticagrelor
ISSN:	1522-9645, 1522-9645
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!